Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases.
$0.45-5.40%
报价 2026-11-16
市值
$124.6M
EV
$48.9M
PE (TTM)
–
预期 PE (FY2026)
–
52 周区间距高点 -74.5%
$0.40$1.76
筛选结果
pipeline · 2026-11-16Filter✗ 高增长✗ Cheap✗ GARP
excluded industry: Biotechnology
研究结论
还没有研究记录。先生成 L2 基本面报告(约 1–3 分钟),结论会显示在这里。
去生成基本面报告 →历史股价
加载中…
事件
0 条 · 随区间与图例筛选该区间内无事件。
同行对比
FMP 同行列表 · 2026-05-16| 公司 | 市值 | 今日 | 预期营收增速 | 毛利率 | PE | EV/EBITDA | P/FCF | 池 |
|---|---|---|---|---|---|---|---|---|
| AKBAAkebia Therapeutics, Inc. | $124.6M | -5.4% | -5.1% | 78.9% | – | – | 10.6x | |
| CRVSCorvus Pharmaceuticals, Inc. | $894.1M | -0.4% | +100.0% | 0% | – | – | – | |
| RIGLRigel Pharmaceuticals, Inc. | $823.4M | -1.6% | +4.5% | 91.4% | 2.7x | 9.1x | 11.1x | |
| OLMAOlema Pharmaceuticals, Inc. | $644.8M | -2.6% | – | 0% | – | – | – | |
| FDMT4D Molecular Therapeutics, Inc. | $623.7M | -7.7% | -59.1% | 42% | – | – | – | |
| ZVRAZevra Therapeutics, Inc. | $550.4M | +1.9% | +53.1% | 95% | 9.1x | 6.8x | 18.0x | |
| PRTAProthena Corporation plc | $409.3M | -2.3% | – | 95.3% | – | – | – | |
| CMPXCompass Therapeutics, Inc. | $119.1M | -14.5% | -125.5% | 0% | – | – | – | |
| GOSSGossamer Bio, Inc. | $67.2M | +0.1% | -57.8% | 99.6% | – | – | – | |
| 同行中位数 | – | – | -26.7% | 66.7% | 5.9x | 8.0x | 14.5x |
研究全文
L2 基本面 memo
尚无基本面 memo
点击「生成基本面报告」——基于最新 filings、电话会纪要与分析师共识生成 L2 memo。
财务报表
暂无季度数据(首次研究运行后填充)。